Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: GC Corp.

Market Cap 489B 322M 278M 257M 240M 450M 30.61B 457M 3.04B 1.18B 14.89B 1.21B 1.18B 51.7B P/E Ratio 2024
33.4x
P/E Ratio 2025 -10.4x
Enterprise Value 1,883B 1.24B 1.07B 988M 926M 1.74B 118B 1.76B 11.72B 4.55B 57.38B 4.65B 4.56B 199B EV / Sales 2024
0.83x
EV / Sales 2025 0.86x
Free-Float
44.46%
Yield 2024
2.89%
Yield 2025 -
05-27 Green Cross Holdings to divest 460 billion won worth of stake in Curevo RE
05-15 GC Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-30 Green Cross Holdings Corporation acquired 22.08% stake in GREEN CROSS WellBeing Corporation from GC Biopharma Corp. for KRW 50.5 billion. CI
03-18 GC Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-10 Green Cross Holdings Corporation announces Annual dividend, payable on April 17, 2026 CI
11-14 Green Cross Holdings Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
14/08/25 Green Cross Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
18/06/25 Green Cross Holdings Corporation agreed to acquire an additional 23.56% stake in GC Care for KRW 71.9 billion. CI
15/05/25 Green Cross Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
18/03/25 Green Cross Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2024 CI
14/11/24 Green Cross Holdings Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
05/11/24 China Resources Boya Bio-pharmaceutical Group Co.,Ltd completed the acquisition of 100% stake in Green Cross Hk Holdings Limited from Green Cross Holdings Corporation, Synaptic 1st Private Equity Fund and others for CNY 1.82 billion. CI
03/09/24 Feldan Bio Inc. announced that it has received CAD 37.5 million in funding from Green Cross Holdings Corporation, Amgen Ventures, Investissement Québec, Investment Arm, Genesys Capital Partners Inc., Fonds de solidarité FTQ and other investors CI
1 day-5.64%
1 week-2.10%
Current month-17.11%
1 month-18.62%
3 months-23.83%
6 months-35.60%
Current year-32.73%
1 week 9,580
Extreme 9580
11,350
1 month 9,580
Extreme 9580
18,010
Current year 9,580
Extreme 9580
18,010
1 year 9,580
Extreme 9580
18,010
3 years 9,580
Extreme 9580
18,490
5 years 9,580
Extreme 9580
36,550
10 years 9,580
Extreme 9580
56,300
Manager TitleAgeSince
Chief Executive Officer 52 28/02/2010
Chief Executive Officer 72 24/03/2010
Director of Finance/CFO 53 -
Director TitleAgeSince
Chairman 72 16/12/2010
Director/Board Member 76 28/02/2009
Director/Board Member 52 28/02/2010
Date Insider Type Main position Quantity % Market Cap.
24/04/25Buy

Chief Executive Officer

3,191 0.0068%
24/04/25Buy

Chief Executive Officer

1,234 0.0026%
24/04/25Buy

Chief Executive Officer

15,000 0.0319%
Change 5-day change 1-year change 3-year change Capi.($)
-5.64%-2.10%-37.73%-31.35% 338M
-2.41%+0.69%+40.12%+154.01% 1,035B
+1.07%+5.57%+55.14%+50.53% 574B
+1.32%+1.24%+18.92%+64.81% 397B
+0.77%+0.77%+21.19%+15.95% 324B
-0.85%-0.68%+23.44%+14.94% 281B
+0.44%+5.39%+25.86%+35.39% 278B
+1.66%+1.20%-44.41%-47.37% 193B
+0.32%+2.78%+21.72%+62.37% 191B
-0.22%-2.78%+14.90%+60.77% 156B
Average -0.37%+2.58%+13.91%+38.01% 343.03B
Weighted average by Cap. +0.22%+2.39%+28.93%+71.61%

Financials

2024 2025
Net sales 2,205B 1.45B 1.26B 1.16B 1.08B 2.03B 138B 2.06B 13.73B 5.33B 67.2B 5.45B 5.34B 233B 2,451B 1.62B 1.4B 1.29B 1.21B 2.26B 154B 2.29B 15.26B 5.93B 74.71B 6.06B 5.93B 259B
Net income 24.03B 15.83M 13.69M 12.61M 11.82M 22.15M 1.51B 22.46M 150M 58.07M 732M 59.39M 58.14M 2.54B -69.51B -45.81M -39.62M -36.49M -34.2M -64.09M -4.36B -64.99M -433M -168M -2.12B -172M -168M -7.36B
Net Debt 1,042B 687M 594M 547M 513M 961M 65.29B 974M 6.49B 2.52B 31.76B 2.58B 2.52B 110B 1,394B 919M 795M 732M 686M 1.29B 87.34B 1.3B 8.68B 3.37B 42.49B 3.45B 3.37B 147B
Logo GC Corp.
Green Cross Holdings is a Korea-based holding company principally engaged in the manufacture and distribution of pharmaceuticals. The Company operates its business through five segments. The Pharmaceutical Manufacturing and Sale segment mainly manufactures and sells blood products, general pharmaceuticals, vaccines and over-the-counter (OTC) drugs. The Medical Service and System Development and Supply segment primarily provides healthcare services. The Diagnostic and Analysis segment mainly engages in blood diagnostics and genetic analysis business. The Leasing and Service Business segment is primarily involved in the real estate leasing and the management of affiliated group companies. The Other segment mainly operates livestock operation and other business.
Employees
144
Date Price Change Volume
12/06/26 10,710.00 -5.64% 225,385
11/06/26 11,350.00 +11.49% 1,021,652
10/06/26 10,180.00 +3.14% 200,270
09/06/26 9,870.00 +1.96% 222,747
08/06/26 9,680.00 -7.28% 313,859
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. A005250 Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!